Skip to main content
. 2021 Mar 8;87(10):3643–3646. doi: 10.1111/bcp.14800

FIGURE 1.

FIGURE 1

Potential harms and benefits of dual SGLT (1 and 2) inhibition in COVID‐19‐induced diabetes. Abbreviations: ACE2, angiotensin‐converting enzyme 2; COVID‐19, coronavirus disease 2019; DKA, diabetic ketoacidosis; GI, gastrointestinal; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; SGLT, sodium‐glucose co‐transporters